With the other premium services, you can dive deep into additional metrics, portfolios, commentary and information about ...

Shares in the industry offer attractive opportunities even after the sector’s big run this year, according to Jefferies.

After a weak first half, the drug and biotech sector has recovered in the past 2-3 months with large drugmakers like Pfizer, ...

Geron Corporation, a Bay Area biotech company that’s ramping up sales of its first commercial drug, announced on Thursday that it’s laying off a third of its staff.

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

A combination of a relatively low-risk approval process, growing sales, and a very attractive valuation based on management's peak sales estimations makes this biotech stock attractive.

NDAA package revives stalled measures on US outbound investment and biotech, signalling Capitol Hill's hardened stance ...

Detailed price information for Amicus Therapeutics (FOLD-Q) from The Globe and Mail including charting and trades.

The biotech sector has been a disaster for investors over the past five years going by a 14% decline compared to an 86% gain ...

Just after market close on Monday, Dyne announced that it has launched an underwritten public offering of $300 million worth ...